Evidence map›Paper›PMID 41111562›Full record

ArticleTobacco induced diseases2025

Expansion of low-price cigarette market and its implications for cigarette tax revenue: Evidence from Bangladesh.

Md Nazmul Hossain, Rumana Huque, S M Abdullah, Nigar Nargis

Abstract read
In one paragraph

Article in Tobacco induced diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Md Nazmul HossainDepartment of Economics, University of Dhaka, Dhaka, Bangladesh.
Rumana HuqueDepartment of Economics, University of Dhaka, Dhaka, Bangladesh.
S M AbdullahDepartment of Economics, University of Dhaka, Dhaka, Bangladesh.
Nigar NargisAmerican Cancer Society, Atlanta, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn Bangladesh, a significantly lower minimum retail price and preferential ad valorem tax rate for low-price cigarettes incentivized manufacturers to avoid tax by expanding the low-price cigarettes market. The effect of this industry response on government tax revenue has not been quantified yet. This study aims to fill this gap.

methodsUsing cigarette sales data (2019-2020) of British American Tobacco (BAT) Bangladesh in the WHO Tobacco Tax Simulation Model, we estimated the gap of actual from potential revenue by simulating four counterfactual scenarios involving government tax interventions and cigarette manufacturers' decision to expand low-price cigarette sales. We analyzed optimal government policy response vis-à-vis manufacturers' actions in a game theoretic framework based on a payoff matrix of tax revenue and industry revenue.

resultsThe revenue gap due to expansion of low-price cigarette sales (scenario 1) was BDT 22.1 billion (US$ 0.26 billion; US$ 1≈ BDT85 in Year 2020), equivalent to around 10% of the collected revenue in 2019-2020. Due to lower minimum price of low-price cigarettes (scenario 2), the revenue gap was BDT 14.7 billion (US$ 0.17 billion). The revenue gap was BDT 30.5 billion (US$ 0.36 billion) for the lower minimum price and lower excise tax rate of low-price cigarettes (scenario 3). The revenue gap due to lower minimum price, lower excise tax rate of low-price cigarettes and low-price cigarette sales expansion (scenario 4) was BDT 49.4 billion (US$ 0.58 billion).

conclusionsIn Bangladesh, revising the tiered excise tax structure by raising prices in the low-tier and unifying tax rates across tiers can curb tax avoidance, boost government revenue, and promote public health.

Indexed as

Bangladeshcigarette tax revenuelow priced cigarettestax simulationtobacco industry response

Identifiers

PMID41111562
PMCPMC12535224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.